Reproduction de : Thèse doctorat : Pharmacie. Pharmacognosie : Reims : 2005. / Bibliogr. p.239-248. Index.

A hipóxia-isquemia neonatal (HI) faz parte da etiologia de diversas patologias neurológicas e é causa de graves sequelas. Os mecanismos patofisiológicos dessa lesão começam com o insulto imediato após a HI e se estendem por dias ou semanas, pelo aumento da liberação de espécies reativas de oxigênio associada a redução da defesas anti-oxidantes e reação glial, sendo a lesão secundária parte crucial no processo que culmina no dano final. A acetilcolina (ACh) é um neurotransmissor do sistema nervoso central (SNC) que parece ter uma importante ação neuroprotetora após a HI. A acetilcolinaesterase (AChE) é responsável pela degradação da ACh, inibidores dessa enzima vêm sendo utilizados para o tratamento de danos neurológicos. Sua ação positiva sobre a HI foi demonstrada em estudos realizados em nosso laboratório, onde a administração do extrato de Huperzia quadrifariata (inibidor de AChE) reduziu os déficits cognitivos e histológicos causados por essa lesão Para avaliar os efeitos das administrações pré e pós-hipóxia de galantamina, inibidor da AChE, no modelo de HI perinatal, ratos Wistar no 7º dia de vida pós-natal (DPN7) foram submetidos à combinação da oclusão unilateral da artéria carótida direita e exposição a uma atmosfera hipóxica (8% de O2) durante 60 minutos. Foram aplicadas injeções intraperitoniais de salina para os grupos Sham e HI+Salina (HIS) e de galantamina nos grupos HI+Galantamina 5 mg/kg pré-hipóxia (HIG5-Pré), HI+Galantamina 10 mg/kg pré-hipóxia (HIG10-Pré), HI+Galantamina 5 mg/kg pós-hipóxia (HIG5-Pós) e HI+Galantamina 10 mg/kg pós-hipóxia (HIG10-Pós). Os grupos Pré receberam galantamina imediatamente antes da hipóxia e os grupos Pós nos intervalos de 1, 24, 48 e 72 horas após a cirurgia. No DPN45 foi feita a análise do volume das estruturas encefálicas que demonstrou a redução do volume do hipocampo do grupo HIS em relação ao Sham e uma prevenção desse efeito no grupo HIG10-Pré, mas não nos demais grupos. Análises bioquímicas foram feitas no hipocampo ipsilesional 24 horas após a lesão e revelaram: através da citometria de fluxo uma redução na sobrevivência de neurônios no grupo HIS em relação ao Sham que foi prevenida no grupo HIG10-Pré; através de ELISA uma hipertrofia dos astrócitos no grupo HIS que foi revertida no grupo HIG10-Pré e um aumento na atividade da enzima anti-oxidante catalase. O tratamento pré-hipóxia com galantamina foi capaz de prevenir os déficits histológicos, aumentar a sobrevivência celular, reduzir a reação astrocitária e aumentar a atividade anti-oxidante em ratos submetidos à HI. / Neonatal hypoxia ischemia (HI) has a role in etiology of several neurological pathologies and causes severe sequelae. The pathophysiological mechanisms of this lesion start immediately after HI and last for days or weeks, with the secondary injury being a crucial part the process that culminates in the final damage. Acetylcholine (ACh) is a neurotransmitter of the central nervous system that seems to have an important neuroprotective action after HI. Acetylcholinesterase (AChE) degradates ACh and inhibitors of this enzyme have been used to treat neurological damage. Its positive action on HI has been demonstrated in studies performed in our laboratory, where the administration of the alkaloid extract of Huperzia quadrifariata (An inhibitor of AChE) reduced the cognitive and histological deficits caused by this lesion. To evaluate the effects of the pre and post-hypoxia administrations of galantamine, a cholinesterase inhibitor, in the model oh perinatal HI, Wistar rats in the post-natal day 7 (PND7) were subjected to a combination of unilateral occlusion of the right charotid artery and of exposure to a hypoxic exposure (8% O2) for 60 minutes. Intraperitoneal injections of saline in the groups Sham anf HI+Saline (HIS) and of galantamine in the groups HI+Galantamine 5 mg/kg pre-hypoxia (HIG5-Pre), HI+Galantamine 10 mg/kg pre-hypoxia (HIG10-Pre), HI+Galantamine 5 mg/kg post-hypoxia (HIG5-Post) and HI+Galantamine 10 mg/kg post-hypoxia (HIG5-Post). The Pre groups received galantamine immediately before hypoxia and the Post groups in the intervals of 1, 24, 48 and 72 hours after HI. On PND45 the analysis of the volume of brain structures showed a reduction of the volume of the ipsilesional hippocampus in the HIS group when compared to the sham and a prevention of this effect in the HIG10-Pre, but not in any other group. Biochemical analysis was performed in the ipsilesional hippocampus 24 hours after the lesion and revealed: a reduction of the number of surviving neurons in the HIS group when compared to the Sham that was prevented in the HIG10-Pre; a hypertrophy of the astrocytes in the HIS group that was prevented in the HIG10-Pre group and an increase in the activity of the anti-oxidant enzyme catalase in the HIG10-Pre group. The treatment with galantamine was able to prevent the histological deficits, increase the survival of neurons, reduce astrocytic reaction and increase the anti-oxidant activity in rats submitted to HI.

Cholinesterase inhibitors (ChEIs) are the first line pharmacotherapy for the symptoms of Alzheimer’s disease (AD). Though ChEIs offer modest cognitive benefits in early AD, literature addressing their continued use in severe AD is scarce. This study assessed the safety of discontinuing ChEIs in institutionalized moderate-severe AD patients. Twenty-six patients were randomized, double-blind to ChEI continuation or placebo for 8-weeks. Vitals, weight (kg) and adverse events (AEs) were monitored biweekly. Chi-square test revealed no significant association between semi-blinded treatment allocation and AE occurrence (χ²=(1,26)=0.99, p=0.32). Groups showed no differences on clinically significant weight loss (χ²=(1,26) =1.9, p=0.17), mean weight loss (F=.531, p= .473), pulse rate (F=.624, p=.437), or side effects (F=.224, p=.640). Preliminary results suggest that either ChEIs are well tolerated or that these drugs are no longer providing therapeutic benefit. Study completion (recruitment of 60 patients and unblinding) will generate more comprehensive data for determination of safe ChEI discontinuation guidelines.

Cholinesterase inhibitors (ChEIs) are the first line pharmacotherapy for the symptoms of Alzheimer’s disease (AD). Though ChEIs offer modest cognitive benefits in early AD, literature addressing their continued use in severe AD is scarce. This study assessed the safety of discontinuing ChEIs in institutionalized moderate-severe AD patients. Twenty-six patients were randomized, double-blind to ChEI continuation or placebo for 8-weeks. Vitals, weight (kg) and adverse events (AEs) were monitored biweekly. Chi-square test revealed no significant association between semi-blinded treatment allocation and AE occurrence (χ²=(1,26)=0.99, p=0.32). Groups showed no differences on clinically significant weight loss (χ²=(1,26) =1.9, p=0.17), mean weight loss (F=.531, p= .473), pulse rate (F=.624, p=.437), or side effects (F=.224, p=.640). Preliminary results suggest that either ChEIs are well tolerated or that these drugs are no longer providing therapeutic benefit. Study completion (recruitment of 60 patients and unblinding) will generate more comprehensive data for determination of safe ChEI discontinuation guidelines.

Background: Dementia leads to progressive cognitive and functional decline. Population aging is a concern, and the healthcare system must refocus its limited resources to keep up with service demands. Three cholinesterase inhibitors (ChEIs) – donepezil, galantamine and rivastigmine – have been approved for the treatment of dementia and are covered under Ontario’s formulary plan, but there has been little research regarding their economic impact. Methods: The purpose of this study was to describe the patterns of use of ChEIs, and to assess associated health resource utilization and costs to Ontario’s healthcare system. Anonymized patient-level data from seven provincial administrative databases were linked at the Institute for Clinical and Evaluative Sciences at Queen’s University. First-time users of ChEIs aged 66 years and older were identified between April 1st, 2004 and March 31st, 2009, and were followed until treatment discontinuation or up to one year following their index date. Health resource use was classified into six care categories: prescription drugs, physicians, long-term care, home care nursing, emergency department, and hospitalizations. Chi-square, Kruskal-Wallis ANOVA and linear regression were employed to compare resource use between users of the three ChEIs. Results: In the cohort (N=40,057), the majority were prescribed donepezil (n=24,347), were female (60.5%) and had at least one other co-morbid disease. The odds of discontinuation were 1.47 (1.36, 1.60) and 1.26 (1.17, 136), higher for rivastigmine users than galantamine and donepezil users, respectively. Between 2005 and 2008, overall healthcare costs increased from $95.2 million to $106.1 million. Prescription drugs comprised 33% of all healthcare costs. ChEIs accounted for half of all prescription drug costs. Overall mean annual healthcare system cost per patient was $12,679.47 ($12,510.86, $12,848.08). Predictors of overall healthcare costs included long-term care, co-morbidity status, hospitalization and hip fractures. Conclusions: Prescription drugs account for a substantial proportion of healthcare costs for patients with dementia, and the amount attributable to ChEIs alone is significant. Knowing the health service utilization patterns for dementia patients can help healthcare professionals and decision-makers plan patient care and timely resource allocation. The results stress the utility of administrative databases and the need for further research for this disease. / Thesis (Master, Community Health & Epidemiology) -- Queen's University, 2011-11-01 15:49:58.417

The α7 nicotinic acetylcholine receptor (nAChR) is involved in learning and memory, synaptic plasticity, neuroprotection, inflammation, and presynaptic regulation of neurotransmitter release. Alzheimer’s disease (AD), a neurodegenerative disease characterized by diminished cognitive abilities, memory loss, and neuropsychiatric disturbances, is associated with a loss of nAChRs. Similarly, traumatic brain injury (TBI) may result in long term neurobehavioral changes exemplified by cognitive dysfunction. Deficits in α7 nAChR expression have previously been shown in experimental TBI and may be related to cognitive impairment experienced in patients following TBI. The purpose of this dissertation was to investigate changes in α7 nAChR expression in models of neurodegeneration and determine if allosteric modulation of the nAChR facilitates functional recovery following experimental TBI through changes in nAChRs. Experimental models employed include a transgenic mouse model of AD that overexpresses the amyloid precursor protein (APPswe mice) and the controlled cortical impact injury model of TBI in rats. Quantitative receptor autoradiography using α-[125I]-bungarotoxin and [125I]-epibatidine and in situ hybridization were used to investigate changes in nAChR density and mRNA expression, respectively. In the first study, the effects of aging and β-amyloid on α7 nAChR expression were evaluated in APPswe mice. Hippocampal α7 nAChR density was significantly upregulated in APPswe mice compared to wild-type mice. It is postulated that elevated Aβ levels bind to the α7 nAChR resulting in upregulation. In a second study, galantamine, a medication used in the treatment of AD, was administered subchronically following experimental TBI to determine if treatment could facilitate cognitive recovery and affect nAChR expression. Interestingly, the results indicate TBI interferes with agonist mediated upregulation of nAChRs, and galantamine did not improve function in a behavioral task of learning a memory. In a third study, the regulation of TBI related deficits in α7 nAChRs was examined 48 hours following injury. α7 nAChR deficits occurred with a reduction in α7 mRNA in several hippocampal regions and non-α7 nAChR deficits occurred with a reduction in α4 mRNA in the metathalamus. The results of these studies suggest AD and TBI may involve complex but parallel processes contributing to the regulation of α7 nAChRs.

A hipóxia-isquemia neonatal (HI) faz parte da etiologia de diversas patologias neurológicas e é causa de graves sequelas. Os mecanismos patofisiológicos dessa lesão começam com o insulto imediato após a HI e se estendem por dias ou semanas, pelo aumento da liberação de espécies reativas de oxigênio associada a redução da defesas anti-oxidantes e reação glial, sendo a lesão secundária parte crucial no processo que culmina no dano final. A acetilcolina (ACh) é um neurotransmissor do sistema nervoso central (SNC) que parece ter uma importante ação neuroprotetora após a HI. A acetilcolinaesterase (AChE) é responsável pela degradação da ACh, inibidores dessa enzima vêm sendo utilizados para o tratamento de danos neurológicos. Sua ação positiva sobre a HI foi demonstrada em estudos realizados em nosso laboratório, onde a administração do extrato de Huperzia quadrifariata (inibidor de AChE) reduziu os déficits cognitivos e histológicos causados por essa lesão Para avaliar os efeitos das administrações pré e pós-hipóxia de galantamina, inibidor da AChE, no modelo de HI perinatal, ratos Wistar no 7º dia de vida pós-natal (DPN7) foram submetidos à combinação da oclusão unilateral da artéria carótida direita e exposição a uma atmosfera hipóxica (8% de O2) durante 60 minutos. Foram aplicadas injeções intraperitoniais de salina para os grupos Sham e HI+Salina (HIS) e de galantamina nos grupos HI+Galantamina 5 mg/kg pré-hipóxia (HIG5-Pré), HI+Galantamina 10 mg/kg pré-hipóxia (HIG10-Pré), HI+Galantamina 5 mg/kg pós-hipóxia (HIG5-Pós) e HI+Galantamina 10 mg/kg pós-hipóxia (HIG10-Pós). Os grupos Pré receberam galantamina imediatamente antes da hipóxia e os grupos Pós nos intervalos de 1, 24, 48 e 72 horas após a cirurgia. No DPN45 foi feita a análise do volume das estruturas encefálicas que demonstrou a redução do volume do hipocampo do grupo HIS em relação ao Sham e uma prevenção desse efeito no grupo HIG10-Pré, mas não nos demais grupos. Análises bioquímicas foram feitas no hipocampo ipsilesional 24 horas após a lesão e revelaram: através da citometria de fluxo uma redução na sobrevivência de neurônios no grupo HIS em relação ao Sham que foi prevenida no grupo HIG10-Pré; através de ELISA uma hipertrofia dos astrócitos no grupo HIS que foi revertida no grupo HIG10-Pré e um aumento na atividade da enzima anti-oxidante catalase. O tratamento pré-hipóxia com galantamina foi capaz de prevenir os déficits histológicos, aumentar a sobrevivência celular, reduzir a reação astrocitária e aumentar a atividade anti-oxidante em ratos submetidos à HI. / Neonatal hypoxia ischemia (HI) has a role in etiology of several neurological pathologies and causes severe sequelae. The pathophysiological mechanisms of this lesion start immediately after HI and last for days or weeks, with the secondary injury being a crucial part the process that culminates in the final damage. Acetylcholine (ACh) is a neurotransmitter of the central nervous system that seems to have an important neuroprotective action after HI. Acetylcholinesterase (AChE) degradates ACh and inhibitors of this enzyme have been used to treat neurological damage. Its positive action on HI has been demonstrated in studies performed in our laboratory, where the administration of the alkaloid extract of Huperzia quadrifariata (An inhibitor of AChE) reduced the cognitive and histological deficits caused by this lesion. To evaluate the effects of the pre and post-hypoxia administrations of galantamine, a cholinesterase inhibitor, in the model oh perinatal HI, Wistar rats in the post-natal day 7 (PND7) were subjected to a combination of unilateral occlusion of the right charotid artery and of exposure to a hypoxic exposure (8% O2) for 60 minutes. Intraperitoneal injections of saline in the groups Sham anf HI+Saline (HIS) and of galantamine in the groups HI+Galantamine 5 mg/kg pre-hypoxia (HIG5-Pre), HI+Galantamine 10 mg/kg pre-hypoxia (HIG10-Pre), HI+Galantamine 5 mg/kg post-hypoxia (HIG5-Post) and HI+Galantamine 10 mg/kg post-hypoxia (HIG5-Post). The Pre groups received galantamine immediately before hypoxia and the Post groups in the intervals of 1, 24, 48 and 72 hours after HI. On PND45 the analysis of the volume of brain structures showed a reduction of the volume of the ipsilesional hippocampus in the HIS group when compared to the sham and a prevention of this effect in the HIG10-Pre, but not in any other group. Biochemical analysis was performed in the ipsilesional hippocampus 24 hours after the lesion and revealed: a reduction of the number of surviving neurons in the HIS group when compared to the Sham that was prevented in the HIG10-Pre; a hypertrophy of the astrocytes in the HIS group that was prevented in the HIG10-Pre group and an increase in the activity of the anti-oxidant enzyme catalase in the HIG10-Pre group. The treatment with galantamine was able to prevent the histological deficits, increase the survival of neurons, reduce astrocytic reaction and increase the anti-oxidant activity in rats submitted to HI.

A hipóxia-isquemia neonatal (HI) faz parte da etiologia de diversas patologias neurológicas e é causa de graves sequelas. Os mecanismos patofisiológicos dessa lesão começam com o insulto imediato após a HI e se estendem por dias ou semanas, pelo aumento da liberação de espécies reativas de oxigênio associada a redução da defesas anti-oxidantes e reação glial, sendo a lesão secundária parte crucial no processo que culmina no dano final. A acetilcolina (ACh) é um neurotransmissor do sistema nervoso central (SNC) que parece ter uma importante ação neuroprotetora após a HI. A acetilcolinaesterase (AChE) é responsável pela degradação da ACh, inibidores dessa enzima vêm sendo utilizados para o tratamento de danos neurológicos. Sua ação positiva sobre a HI foi demonstrada em estudos realizados em nosso laboratório, onde a administração do extrato de Huperzia quadrifariata (inibidor de AChE) reduziu os déficits cognitivos e histológicos causados por essa lesão Para avaliar os efeitos das administrações pré e pós-hipóxia de galantamina, inibidor da AChE, no modelo de HI perinatal, ratos Wistar no 7º dia de vida pós-natal (DPN7) foram submetidos à combinação da oclusão unilateral da artéria carótida direita e exposição a uma atmosfera hipóxica (8% de O2) durante 60 minutos. Foram aplicadas injeções intraperitoniais de salina para os grupos Sham e HI+Salina (HIS) e de galantamina nos grupos HI+Galantamina 5 mg/kg pré-hipóxia (HIG5-Pré), HI+Galantamina 10 mg/kg pré-hipóxia (HIG10-Pré), HI+Galantamina 5 mg/kg pós-hipóxia (HIG5-Pós) e HI+Galantamina 10 mg/kg pós-hipóxia (HIG10-Pós). Os grupos Pré receberam galantamina imediatamente antes da hipóxia e os grupos Pós nos intervalos de 1, 24, 48 e 72 horas após a cirurgia. No DPN45 foi feita a análise do volume das estruturas encefálicas que demonstrou a redução do volume do hipocampo do grupo HIS em relação ao Sham e uma prevenção desse efeito no grupo HIG10-Pré, mas não nos demais grupos. Análises bioquímicas foram feitas no hipocampo ipsilesional 24 horas após a lesão e revelaram: através da citometria de fluxo uma redução na sobrevivência de neurônios no grupo HIS em relação ao Sham que foi prevenida no grupo HIG10-Pré; através de ELISA uma hipertrofia dos astrócitos no grupo HIS que foi revertida no grupo HIG10-Pré e um aumento na atividade da enzima anti-oxidante catalase. O tratamento pré-hipóxia com galantamina foi capaz de prevenir os déficits histológicos, aumentar a sobrevivência celular, reduzir a reação astrocitária e aumentar a atividade anti-oxidante em ratos submetidos à HI. / Neonatal hypoxia ischemia (HI) has a role in etiology of several neurological pathologies and causes severe sequelae. The pathophysiological mechanisms of this lesion start immediately after HI and last for days or weeks, with the secondary injury being a crucial part the process that culminates in the final damage. Acetylcholine (ACh) is a neurotransmitter of the central nervous system that seems to have an important neuroprotective action after HI. Acetylcholinesterase (AChE) degradates ACh and inhibitors of this enzyme have been used to treat neurological damage. Its positive action on HI has been demonstrated in studies performed in our laboratory, where the administration of the alkaloid extract of Huperzia quadrifariata (An inhibitor of AChE) reduced the cognitive and histological deficits caused by this lesion. To evaluate the effects of the pre and post-hypoxia administrations of galantamine, a cholinesterase inhibitor, in the model oh perinatal HI, Wistar rats in the post-natal day 7 (PND7) were subjected to a combination of unilateral occlusion of the right charotid artery and of exposure to a hypoxic exposure (8% O2) for 60 minutes. Intraperitoneal injections of saline in the groups Sham anf HI+Saline (HIS) and of galantamine in the groups HI+Galantamine 5 mg/kg pre-hypoxia (HIG5-Pre), HI+Galantamine 10 mg/kg pre-hypoxia (HIG10-Pre), HI+Galantamine 5 mg/kg post-hypoxia (HIG5-Post) and HI+Galantamine 10 mg/kg post-hypoxia (HIG5-Post). The Pre groups received galantamine immediately before hypoxia and the Post groups in the intervals of 1, 24, 48 and 72 hours after HI. On PND45 the analysis of the volume of brain structures showed a reduction of the volume of the ipsilesional hippocampus in the HIS group when compared to the sham and a prevention of this effect in the HIG10-Pre, but not in any other group. Biochemical analysis was performed in the ipsilesional hippocampus 24 hours after the lesion and revealed: a reduction of the number of surviving neurons in the HIS group when compared to the Sham that was prevented in the HIG10-Pre; a hypertrophy of the astrocytes in the HIS group that was prevented in the HIG10-Pre group and an increase in the activity of the anti-oxidant enzyme catalase in the HIG10-Pre group. The treatment with galantamine was able to prevent the histological deficits, increase the survival of neurons, reduce astrocytic reaction and increase the anti-oxidant activity in rats submitted to HI.

No description available.

The serotonergic and cholinergic systems are jointly involved in regulating sleep but this balance is theorized to be disturbed in depressed individuals (Janowsky 1972, Jouvet 1972). One potential cause of disturbed neurotransmission is genetic predisposition. The G(-1019) allele of the 5-HT1A receptor predicts an increased risk for depression compared to the wild-type C(-1019) allele. The goal of this study was to use pharmacological probes in normal controls to model the serotonergic/cholinergic imbalance of depression and its associated abnormalities in sleep structure while controlling for 5-HT1A receptor genotype. Seventeen healthy female participants homozygous for either C (n=11) or G (n=6) alleles, age 18-27 years were tested on four non-consecutive nights. Participants were given galantamine (an anti-acetylcholinesterase), buspirone (a serotonergic agonist), both drugs together, or placebos before sleeping. Buspirone suppressed tonic REM: there was a significant increase in REM latency (p<0.001). Galantamine increased tonic REM sleep, leading to more time spent in stage REM (p<0.001) and shorter REM latency (p<0.01). Galantamine and buspirone given together tended to negate the effects of each other on REM sleep measures but disrupted sleep more than either drug alone, showing lower SE and N3% and increased awakenings, Wake% and N1% (p<0.019). There was no main effect of genotype nor was there a significant multivariate interaction between genotype and drug condition. These findings are partially consistent with the literature about sleep in depression, notably short REM latency, higher percentage of total sleep time spent in REM, and increased sleep fragmentation. The C/G mutation in the 5-HT1A receptor does not appear to cause noticeable differences in the sleep patterns of healthy young females.